Nanoparticle delivery technology that transports compounds to the bloodstream and cells can increase bioavailability and reduce adverse effects of cannabinoids and bioactive compounds, says NanoSphere Health Sciences.
Porton Biopharma will look to develop GMP manufacturing capabilities for Clostridia bacteria as part of a UK collaboration developing aimed at developing microbiome targeted therapeutics.
‘Splinter-like’ nanostructures have been developed by researchers in the US to deliver biomolecules straight into patient cells for immune-oncology and gene therapies.
A new method to predict the physical stability of drug candidates is attracting interest from pharmaceutical companies who could use the technology to de-risk early development.
Takeda Pharmaceuticals will work with Wave Life Sciences to develop nucleic acid therapies for central nervous system disorders, including Huntington’s and Lou Gehrig’s disease.
AMAG has received approval for its preterm birth risk reduction product combining the drug product supplied by Pfizer and Antares Pharma’s auto-injection system.
The Republic of Ireland will move its population from short-acting to extended half-life haemophilia therapies, under an exclusive two-year deal with Sobi.
A patient-controlled injector and a prefilled pen for patients with hand dexterity issues were among the drug delivery technologies celebrated at PharmaPack Europe’s awards this year.
Vical has dismissed 40 employees and abandoned a Phase III vaccine candidate in a reshuffle it says allows for greater resources on HSV-2 and antifungal trials.
The US FDA has asked Braeburn Pharmaceuticals for more information regarding its sustained-release subcutaneous buprenorphine injection in a complete response letter (CRL).
Pfizer says ongoing remediation to the quality validation process at its supplier has resulted in a shortage of EpiPen auto-injectors in the 0.3 mg format.
Vector-based vaccine tech firm Vaccitech has secured £20m ($27.1m) in venture capital with investors Google Ventures, Sequoia China, Neptune Ventures and Oxford Sciences Innovation.
Research looks to microneedle patch to combat antimicrobial resistance
A skin patch designed to deliver antibiotics directly into the bloodstream could prevent the development of antimicrobial resistance in gut bacteria, say scientists in Ireland.
Arrowhead Pharmaceuticals says it is looking to move six candidates into the clinic within the next year thanks to its newly unveiled RNAi delivery platform.
Emergent BioSolutions says it is looking to expand auto-injector manufacturing capacity due to growing demand for its nerve agent antidote product Trobigard.
Novo Nordisk’s once-weekly diabetes treatment Ozempic has been given the US FDA green light, and the firm said it expects approval in Europe and Japan early 2018.
Almac will “eventually” move into sterile injectables says executive Brian Eastwood, adding the market has good potential for growth in the contract manufacturing space.
The US Food and Drug Administration has approved ViiV Healthcare’s two-drug treatment for HIV-1 maintenance, the first time the drugs have been combined into a single pill.
Scientists have developed opioid pain relievers that do not slow or stop breathing – the cause of opiate overdose – they say could reduce the risk of accidental death.
Corium says it is in talks with commercialisation partners for its transdermal Alzheimer’s disease candisate Corplex Donepezil ahead of a potential 2019 launch.
Otsuka Pharmaceutical’s pill embedded with a sensor that digitally verifies if patients have taken their medication has received US approval for mental illness indications.
Evoke Pharma has selected Patheon to commercially manufacture its nasal delivery formulation of metoclopramide Gimoti ahead of a planned US FDA submission next year.
